Venture Capital

With a soaring stock and a breakthrough CAR-T therapy, Immix Biopharma is set to capture investor attention. What's behind the hype for its lead drug, NXC-201?

An Atlanta clinic combines lasers, biologics, and AI to challenge traditional joint surgery. Can a new marketing push make it a national alternative?

As Beijing weaponizes rare earths, one company is already producing the critical alloys America's military needs, sidestepping a decades-long dependency.

After a transformational CEO retires, Byrna Technologies bets on new leadership to navigate the booming, competitive less-lethal defense market.

A new agreement could see South Korea's INNOSPACE launch from Canada, positioning Spaceport Nova Scotia as a key player in the global space race.

Amid a strategic overhaul, Hepion Pharmaceuticals is licensing a novel RNA-based liquid biopsy, aiming to transform early liver cancer detection.

Facing declining revenue, Goodfood adds restructuring and digital experts to its board. Can this shake-up revive the Canadian meal-kit pioneer?

Axxess's upcoming conference tackles AI's role in home health, unveils a new leadership certification, and honors an industry titan. Here's what it means.

Indian EdTech firm EasyShiksha appoints Deepti Barman to lead strategic alliances, signaling a major push to compete on the global stage.

Ziff Davis nets a massive windfall by selling its Connectivity division, including Ookla and Speedtest, to Accenture in a deal reshaping network intelligence.

Modaxo's new brand, Aerivo, emerges from an ADB SAFEGATE acquisition, poised to enhance airport efficiency with its cloud-native Flightivity suite.

A new trial for a cell therapy targeting a rare eye disease offers hope, driven by a patient-advocate's journey and with potential to treat common AMD.

With 74,000 UK mothers losing jobs annually, a new alliance between Momcozy and AllBright uses tech and advocacy to turn the motherhood penalty into power.

The world's top beauty event returns to Paris, showcasing a major shift as ingestible ingredients and holistic wellness redefine the personal care industry.

A massive US$175M investment in EverWind is set to transform Nova Scotia into a clean energy powerhouse, with a groundbreaking Indigenous partnership at its core.

With a pivotal trial for pancreatic cancer looming, Immuneering will detail its novel 'Deep Cyclic Inhibitor' platform and strategy to investors.

Entrepreneur Daniel Gestetner discusses resilience, a $1B exit, and why true success isn't about winning at all costs in a revealing new podcast.

An R&D studio is set to demo real-time AI world generation at GDC, promising a new era of interactive entertainment that runs directly on consumer hardware.

With $14M in new funding, Firmable plans to challenge US sales tech giants by leveraging its proprietary AI-driven data and a proven global playbook.

After selling poppi to PepsiCo for $1.95B, Allison and Stephen Ellsworth hire SolComms to build their next chapter as investors and thought leaders.